SRNE News and Press, Sorrento Therapeutics Inc. From 10/14/20

Sorrento Therapeutics (NASDAQ: SRNE) , a clinical-stage biotech with an extensive COVID-19 product pipeline, is having a rough day today. The biotech's stock is down by a noteworthy 14% as of 10:54 a.m. EDT Wednesday. The culprit? Investors appear to be disappointed at Sorrento'...

Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S. Studies are complementary and address both dose duration and disease stage Rapid enrollment expected for both geographies SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento The...

Gainers: Interpace Biosciences (IDXG) +42%, AnaptysBio (ANAB) +32%, Replimune Group (REPL) +31%, Allscripts Healthcare Solutions (MDRX) +29%, OncoCyte (OCX) +19%.Losers: Cyclerion Therapeutics (CYCN) -47%, Enzo Biochem (ENZ) -17%, So...

Cyclerion Therapeutics (CYCN) -41% after Phase 2 STRONG-SCD study results in patients with Sickle Cell Disease.Sorrento Therapeutics (SRNE) -12%.Aethlon Medical (AEMD) -11%.Enzo Biochem ENZ -10% on FQ4 earnings results.Auris Medical Holding (EARS) -10%.SOS  ...

The U.S. Patent Office has awarded Sorrento Therapeutics (SRNE) patents for 1) Antibody therapeutics that bind CD38, and 2) Disulfide bridging conjugates.Shares are up 5.5% thirty minutes ahead of the close. For further details see: Sorrento Therapeutics awarded anti...

Sorrento Therapeutics (NASDAQ: SRNE) has added another arrow to its COVID-19 quiver . The biotech licensed an adipose-derived mesenchymal stem cell (MSC) treatment from Personalized Stem Cells for patients with acute respiratory distress syndrome associated with COVID-19. Th...

Sorrento Therapeutics (SRNE) enters into an exclusive license agreement with Personalized Stem Cells to acquire global rights to its adipose derived mesenchymal stem cells (or MSCs), which have been cleared for a Phase 1 clinical trial by the FDA.These will be used for patients suff...

SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem Cells, Inc. (PSC) to acquire global rights to its adipose derived mesenchymal stem cells (MSCs) ...

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13 th , 2020. T itle : Sorrento Therapeutics COVID-19 Pipe...

Sorrento Therapeutics (SRNE) files for 996,803 share common stock offering by Selling Shareholder.See below company's ownership structure: For further details see: Sorrento holder to offer 997K shares